Indazole amide compound and application thereof

By developing a new indazolamide compound, the side effects of existing PDE4 inhibitors in the treatment of inflammation, fibrosis and central nervous system diseases have been solved, and the selective inhibition of PDE4B and PDE4D subtypes has been achieved, which has significantly reduced the number of patients with the PDE4B and PDE4D. Cell inflammatory factors were expressed, showing good anti-inflammatory activity and potential therapeutic effects.

CN118994130AActive Publication Date: 2024-11-22CHINA PHARM UNIV
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202410879263.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-22
Estimated Expiration
2044-07-02

AI Technical Summary

Technical Problem

Existing PDE4 inhibitors have gastrointestinal side effects and central nervous system side effects in the treatment of inflammation, fibrosis and central nervous system diseases, and the treatment index is low, making it difficult to meet clinical needs.

Method used

A new indazole amide compound was developed, prepared by condensation reactions, used as a PDE4 inhibitor to improve the selective inhibitory ability of PDE4B and PDE4D subtypes, reduce side effects, and enhance therapeutic index.

Benefits of technology

This compound effectively inhibits PDE4 enzyme activity, significantly reduces the expression of TNF-α in LPS-induced inflammatory factor TV2 cells, demonstrates good anti-inflammatory activity, and is potentially used to treat a variety of inflammatory, fibrotic and central nervous system diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994130A_ABST
    Figure CN118994130A_ABST
Patent Text Reader

Abstract

The invention relates to an indazole amide compound and application thereof. Specifically, the invention provides a compound as shown in a formula I or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has a good inhibition effect on PDE4. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to an indazole amide compound and a use thereof. Background Art

[0002] Phosphodiesterase 4 (PDE4) belongs to the phosphodiesterase family. It is responsible for degrading cyclic adenosine monophosphate (cAMP) in the body. It is the earliest discovered protein in the phosphodiesterase family and has the largest number of members. It regulates the level of intracellular cAMP together with nucleotide cyclase and plays a key role in the homeostasis of cAMP signaling. PDE4 contains four subtypes: A, B, C and D. Among them, subtype C is less expressed in the body. The main subtypes are A, B and D. Each subtype has significant expression differences in different tissues and organs. The subtypes that are currently studied more are B and D. After different splicing, each subtype gene forms a variety of splice variants. According to the upstream conserved regions (UCRs), they can be divided into long, short, ultra-short and dead short types. Among them, the long type of PDE4 contains UCR1 and UCR2, the short type contains only UCR2, and the ultrashort type contains truncated UCR2. Each PDE4 subtype and splicing variant may have its own unique function.

[0003] cAMP is an important signaling molecule that regulates important physiological and pathological processes such as inflammatory response, fibrosis, body damage, and central nervous system function. It can affect the occurrence and development of inflammation, the formation of fibrosis, inflammation and repair after injury, neurogenesis, the establishment of neuronal circuits, cell apoptosis, neural plasticity, sleep, sensory motor gating, emotional stability, memory, and other cognitive functions. As one of the important members regulating cAMP signals, PDE4 has attracted much attention in recent years in the treatment of diseases such as inflammation, fibrosis, damage, and the central nervous system. Related diseases include inflammatory diseases such as chronic obstructive pulmonary disease, asthma, dermatitis, hepatitis, non-alcoholic fatty liver disease, psoriasis, rhinitis, Behcet's syndrome, arthritis, eczema, vitiligo, and ulcerative colitis; fibrotic diseases such as pulmonary fibrosis, liver fibrosis, and cystic fibrosis; injury-related diseases such as lung injury, liver injury, kidney injury, edema, and traumatic brain injury; central nervous system diseases such as Alzheimer's disease, anti-depression, anti-anxiety, multiple sclerosis, stroke, and cognitive improvement.

[0004] PDE4 participates in a variety of physiological functions and is closely related to a variety of diseases by regulating the level of cAMP in the body. The main pathways involved in PDE4 include the cAMP / PKA / CREB signaling pathway and the MAPK / ERK / CREB pathway. By inhibiting the activity of PDE4, the hydrolysis of cAMP is blocked, the cellular level increases, and then activates cAMP-dependent protein kinase A (PKA), activates the cAMP / PKA / CREB and / or MAPK / ERK / CREB signaling pathways, and then regulates the expression of a variety of target genes including BDNF, Bax, PEPCK, IL-2, etc., thereby participating in a variety of physiological and pathological processes related to inflammation, fibrosis, injury, memory and learning.

[0005] A large number of clinical and preclinical studies have shown that regulating PDE4 activity and cAMP levels through inhibitors can play a role in treating a variety of diseases. Currently, there are many PDE4 inhibitors on the market, including roflumilast, apremilast, and criborol. Due to the problems of gastrointestinal side effects and central nervous system side effects of injury drugs, PDE4 inhibitors are still a hot topic of research. Improving the therapeutic index is the main research goal. The main research directions include changing the route of administration, discovering highly active subtype selective inhibitors, dual-target inhibitors, and indication research.

[0006] The above studies show that PDE4 is a druggable target with great potential and has great therapeutic potential in the fields of inflammatory diseases, fibrosis-related diseases, injury-related diseases and central nervous system-related diseases. It is urgent to develop new PDE4 inhibitors for the development of candidate drugs for related diseases. Summary of the invention

[0007] The present invention provides a compound as shown in formula I or a pharmaceutically acceptable salt thereof,

[0008]

[0009] Among them, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 1-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 1-3 Substituted 3-6 membered heterocycloalkyl;

[0010] R 2 is unsubstituted or replaced by R 2-1 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 2-2 substituted 3-6 membered heterocycloalkyl, unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl;

[0011] R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0012] Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0013] R 1-1 and R 3-1 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Carboxyl, -C(=O)-C 1-4 Alkyl, -NHC(=O)-C 1-4 Alkyl or -C(=O)NH-C 1-4 alkyl;

[0014] R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Carboxyl, -C(=O)-C 1-4 Alkyl, -NHC(=O)-C 1-4 Alkyl or -C(=O)NH-C 1-4 alkyl.

[0015] In some embodiments, only the following substituents or groups are defined, and the definitions of the substituents or groups not involved are the same as those described in any other embodiment (hereinafter referred to as "in some embodiments"), R 1is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl.

[0016] In some embodiments, R 2 is unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl.

[0017] In some embodiments, R 2 is unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl.

[0018] In some embodiments, R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl.

[0019] In some embodiments, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-10 membered heterocycloalkyl.

[0020] In some embodiments, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 4-6 membered heterocycloalkyl.

[0021] In some embodiments, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 The substituted 4-, 5- or 6-membered heterocycloalkyl group has a heteroatom selected from one or more of N, O and C(═O), and the number of the heteroatom is 1, 2 or 3.

[0022] In some embodiments, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 The substituted 6-membered heterocycloalkyl group has "a heteroatom selected from N and O, and the number of the heteroatom is 1, 2 or 3".

[0023] In some embodiments, R 1-1 and R 3-1 are each independently halogen.

[0024] In some embodiments, R 1-1 It is a halogen.

[0025] In some embodiments, R 2-3 , R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0026] In some embodiments, R 2-4 , R 2-5 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0027] In some embodiments, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;

[0028] R 2 is unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or R 2-5 substituted 5-6 membered heteroaryl;

[0029] R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0030] Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0031] R 1-1 and R 3-1 are each independently a halogen;

[0032] R 2-3 , R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0033] In some embodiments, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;

[0034] R 2 is unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or R 2-5 substituted 5-6 membered heteroaryl;

[0035] R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0036] Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0037] R 1-1 is a halogen;

[0038] R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0039] In some embodiments, the compound represented by Formula I or a pharmaceutically acceptable salt thereof is a compound represented by Formula I-1 or a pharmaceutically acceptable salt thereof,

[0040]

[0041] Wherein ring A is unsubstituted or substituted by R 3-4 Substituted 3-12 membered heterocycloalkyl; R 1 , R 2 and R 3-4 As defined in Formula I.

[0042] In some embodiments, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;

[0043] R 2 is unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl;

[0044] Ring A is unsubstituted or substituted by R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0045] R 1-1 is a halogen;

[0046] R 2-3 , R 2-4 , R 2-5 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0047] In some embodiments, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;

[0048] R 2 is unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl;

[0049] Ring A is unsubstituted or substituted by R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0050] R 1-1 is a halogen;

[0051] R 2-4 , R 2-5 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0052] In some embodiments, the compound represented by Formula I-1 or a pharmaceutically acceptable salt thereof is a compound represented by Formula I-1A or a pharmaceutically acceptable salt thereof,

[0053]

[0054] Among them, ring A and R 2 As defined in formula I-1.

[0055] In some embodiments, the compound represented by Formula I or a pharmaceutically acceptable salt thereof is a compound represented by Formula I-2 or a pharmaceutically acceptable salt thereof,

[0056]

[0057] Among them, R 3’ and R 4’ Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl; R 1 , R 2 , R 3-1 , R 3-2 and R 3-3 As defined in Formula I.

[0058] In some embodiments, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;

[0059] R 2 is unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14Aryl, unsubstituted or R 2-5 substituted 5-6 membered heteroaryl;

[0060] R 3’ and R 4’ Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0061] R 1-1 and R 3-1 are each independently a halogen;

[0062] R 2-3 , R 2-4 , R 2-5 , R 3-2 and R 3-3 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0063] In some embodiments, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;

[0064] R 2 is unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or R 2-5 substituted 5-6 membered heteroaryl;

[0065] R 3’ and R 4’ Each is independently H, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0066] R 1-1 is a halogen;

[0067] R 2-4 , R 2-5 , R 3-2 and R 3-3 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0068] In some embodiments, the compound represented by Formula I-2 or a pharmaceutically acceptable salt thereof is a compound represented by Formula I-2A or a pharmaceutically acceptable salt thereof,

[0069]

[0070] Among them, R 2 , R 3’ and R 4’ As defined in Formula 1-2.

[0071] In some embodiments, the compound represented by Formula I or a pharmaceutically acceptable salt thereof is a compound represented by Formula I-3 or a pharmaceutically acceptable salt thereof,

[0072]

[0073] Among them, R 2 , R 3 and R 4 As defined in Formula I.

[0074] In some embodiments, R 2 is unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl;

[0075] R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0076] Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0077] R 3-1 is a halogen;

[0078] R 2-3 , R 2-4 , R 2-5 , R 3-2, R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0079] In some embodiments, R 2 is unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or substituted with R 2-5 Substituted 5-6 membered heteroaryl;

[0080] R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl;

[0081] Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl;

[0082] R 3-1 is a halogen;

[0083] R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

[0084] In some embodiments, R 1 , R 3 , R 4 , R 3’ , R 4’ , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R3-2 , R 3-3 and R 3-4 In the C 1-6 The alkyl groups are each independently C 1-4 In some embodiments, R 1 In the C 1-6 The alkyl group is ethyl.

[0085] In some embodiments, R 1 , R 2 , R 3 and R 4 wherein the 3-6 membered cycloalkyl groups are each independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0086] In some embodiments, R 1 and R 2 In the above, the 3-6 membered heterocycloalkyl groups are each independently a 3-6 membered heterocycloalkyl group having "a heteroatom selected from one or more of N, O and S, and the number of heteroatoms is 1, 2 or 3".

[0087] In some embodiments, R 2 In some embodiments, the 3-12 membered heterocycloalkenyl group is a 3-12 membered heterocycloalkenyl group with "heteroatoms selected from one or more of N, O, S and C(=O), and the number of heteroatoms is 1, 2 or 3". In some embodiments, the heterocycloalkenyl group is a 5-12 membered heterocycloalkenyl group with "heteroatoms selected from one or more of N, O, S and C(=O), and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkenyl group is a 5-12 membered heterocycloalkenyl group with "heteroatoms selected from one or more of O, S and C(=O), and the number of heteroatoms is 1, 2 or 3", and has 1-2 carbon-carbon double bonds. In some embodiments, R 2 wherein the 3-12 membered heterocycloalkenyl group is

[0088] In some embodiments, R 2 In the C 6-14 Aryl is phenyl or naphthyl. In some embodiments, the C 6-14 Aryl is phenyl.

[0089] In some embodiments, R 2In the above, the 5-6 membered heteroaryl is a 5-6 membered heteroaryl with "heteroatoms selected from one or more of N, O and S, and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 5-6 membered heteroaryl includes but is not limited to pyrrolyl, furanyl, thienyl, pyridyl or pyranyl. In some embodiments, the 5-6 membered heteroaryl is thienyl or pyridyl.

[0090] In some embodiments, R 3 In the embodiment, the 3-12 membered heterocycloalkyl is a 3-12 membered heterocycloalkyl group with "heteroatoms selected from one or more of N, O, S, C(=O) and S(=O)2, and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl is a 3-10 membered heterocycloalkyl group with "heteroatoms selected from one or more of N, O, S, C(=O) and S(=O)2, and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl is a 3-10 membered heterocycloalkyl group with "heteroatoms selected from one or more of O, C(=O) and S(=O)2, and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl is

[0091] In some embodiments, when R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 When the 3-12 membered heterocycloalkyl is substituted, the 3-12 membered heterocycloalkyl is a 3-12 membered heterocycloalkyl "wherein the heteroatoms are selected from one or more of N, O, S, C(=O) and S(=O)2, and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl is a 3-10 membered heterocycloalkyl "wherein the heteroatoms are selected from one or more of N, O and C(=O), and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl is a 4-, 5- or 6-membered heterocycloalkyl "wherein the heteroatoms are selected from one or more of N, O and C(=O), and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl is azetidine, morpholinyl, pyrrolidinone, piperidinyl, piperazinyl,

[0092]

[0093] In some embodiments, the ring A is a 3-12 membered heterocycloalkyl group with "heteroatoms selected from one or more of N, O, S, C(=O) and S(=O)2, and the number of heteroatoms is 1, 2 or 3". In some embodiments, the ring A is a 3-10 membered heterocycloalkyl group with "heteroatoms selected from one or more of N, O and C(=O), and the number of heteroatoms is 1, 2 or 3". In some embodiments, the 3-12 membered heterocycloalkyl group is a 4-, 5- or 6-membered heterocycloalkyl group with "heteroatoms selected from one or more of N, O and C(=O), and the number of heteroatoms is 1, 2 or 3". In some embodiments, the ring A is azetidine, morpholinyl, pyrrolidinone, piperidinyl, piperazinyl,

[0094] In some embodiments, R 1-1 , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-1 , R 3-2 , R 3-3 and R 3-4 The number of each is independently one or more. 1-1 , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3 -1 , R 3-2 , R 3-3 and R 3-4 The number of is independently 1, 2 or 3.

[0095] In some embodiments, R 1-1 , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-1 , R 3-2 , R 3-3 and R 3-4 In some embodiments, the halogen is fluorine, chlorine or bromine.

[0096] In some embodiments, R1-1 , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-1 , R 3-2 , R 3-3 and R 3-4 In the C 1-4 The alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.

[0097] In some embodiments, R 1-1 , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-1 , R 3-2 , R 3-3 and R 3-4 In the C 1-4 Each alkoxy group is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy. 1-4 Alkoxy is methoxy.

[0098] In some embodiments, R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 In the C 1-4 Haloalkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl substituted by 1, 2 or 3 fluorine, chlorine or bromine. 1-4 Haloalkyl is -CH2F, -CHF2 or -CF3.

[0099] In some embodiments, R 1-1 , R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R3-1 , R 3-2 , R 3-3 and R 3-4 In the C 1-4 Haloalkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy substituted by 1, 2 or 3 fluorine, chlorine or bromine. 1-4 Haloalkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy substituted by 1, 2 or 3 fluorine groups.

[0100] In some embodiments, the compound represented by Formula I or a pharmaceutically acceptable salt thereof is a compound of any of the following structures or a pharmaceutically acceptable salt thereof,

[0101]

[0102]

[0103]

[0104] The present disclosure provides a method for preparing the compound shown in formula I, which comprises: subjecting the compound shown in formula II to a condensation reaction with the compound shown in formula III to obtain the compound shown in formula I.

[0105]

[0106] Among them, R 1 , R 2 , R 3 and R 4 As defined in the compound represented by formula I above.

[0107] In some embodiments, the conditions and operations of the condensation reaction may be conventional conditions and operations for such reactions in the art.

[0108] The present disclosure provides a pharmaceutical composition, which includes the compound shown in Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0109] The present disclosure also provides a use of the compound as shown in Formula I or a pharmaceutically acceptable salt thereof or the pharmaceutical composition in the preparation of a medicament as a PDE4 inhibitor. In some embodiments, the PDE4 inhibitor is a PDE4B and / or PDE4D inhibitor.

[0110] The present disclosure also provides a compound as shown in Formula I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as shown in Formula I for the preparation of a drug for preventing and / or treating a disease associated with PDE4. In some embodiments, the PDE4 is PDE4B and / or PDE4D. In some embodiments, the disease associated with PDE4 is an inflammatory disease, a fibrotic disease, a damaging disease, and a central nervous system disease. In some embodiments, the inflammatory disease includes chronic obstructive pulmonary disease, asthma, dermatitis, hepatitis, non-alcoholic fatty liver disease, psoriasis, rhinitis, Behcet's syndrome, arthritis, eczema, vitiligo, and ulcerative colitis. In some embodiments, the fibrotic disease includes pulmonary fibrosis, liver fibrosis, and cystic fibrosis. In some embodiments, the damaging disease includes lung injury, liver injury, kidney injury, edema, and traumatic brain injury. In some embodiments, the central nervous system disease includes Alzheimer's disease, antidepression, antianxiety, multiple sclerosis, stroke, and cognitive impairment-related diseases.

[0111] The present disclosure also provides a compound as shown in Formula I or a pharmaceutically acceptable salt thereof or the pharmaceutical composition as shown in Formula I for the preparation of a drug for the prevention and / or treatment of inflammatory diseases, fibrotic diseases, damaging diseases and central nervous system diseases. In some embodiments, the inflammatory diseases include chronic obstructive pulmonary disease, asthma, dermatitis, hepatitis, non-alcoholic fatty liver disease, psoriasis, rhinitis, Behcet's syndrome, arthritis, eczema, vitiligo and ulcerative colitis. In some embodiments, the fibrotic diseases include pulmonary fibrosis, liver fibrosis and cystic fibrosis. In some embodiments, the damaging diseases include lung injury, liver injury, kidney injury, edema and traumatic brain injury. In some embodiments, the central nervous system diseases include Alzheimer's disease, antidepression, anti-anxiety, multiple sclerosis, stroke and improved cognition.

[0112] Definitions of terms are described below.

[0113] On the other hand, in the case where the present disclosure does not limit a specific configuration, the disclosed compounds may exist in specific geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present disclosure.

[0114] In addition, the compounds and intermediates of the present disclosure can also exist in different tautomeric forms, and all such forms are included in the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also referred to as prototransfer tautomers) include interconversion via proton migration, such as keto-enol and imine-enamine, lactam-lactim isomerization. The lactam-lactim equilibrium example is between A and B as shown below.

[0115]

[0116] All compounds in the present disclosure can be drawn as either Form A or Form B. All tautomeric forms are within the scope of the present disclosure. The naming of the compounds does not exclude any tautomers.

[0117] The disclosed compounds may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The disclosed compounds containing asymmetric carbon atoms may be isolated in optically pure forms or in racemic forms. Optically pure forms may be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.

[0118] Optically active (R)- and (S)-isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary groups are cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is usually accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., the formation of a carbamate from an amine).

[0119] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 30 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 10 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and further preferably an alkyl group containing 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like.

[0120] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 7 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.; polycyclic cycloalkyls include spirocyclic, fused and bridged cycloalkyls.

[0121] The term "heterocycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more ring atoms is selected from nitrogen, oxygen, C(=O) or S(=O). m (wherein m is an integer from 0 to 2) heteroatoms, but does not include -OO-, -OS- or -SS- ring parts, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 7 ring atoms. Non-limiting examples of monocyclic heterocycloalkyls include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocycloalkyls include spirocyclic, fused ring and bridged heterocycloalkyls. Non-limiting examples of "heterocycloalkyls" include:

[0122]

[0123] etc.

[0124] The heterocycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a heterocycloalkyl, non-limiting examples of which include:

[0125] wait.

[0126] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. The aryl ring may be fused to a heteroaryl, heterocycloalkyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:

[0127]

[0128] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 12 members, more preferably 5 or 6 members. For example. Non-limiting examples include: imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, triazolyl, indazolyl, benzimidazolyl, wait.

[0129] The heteroaryl ring may be fused to an aryl, heterocycloalkyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which include:

[0130]

[0131] The term "spirocyclic" refers to compounds in which two rings share one atom.

[0132] The term "spirocycloalkyl" refers to a polycyclic group in which a carbon atom (called a spiro atom) is shared between 5 to 20 monocyclic rings, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiro atoms shared between rings, spirocycloalkyl is divided into single spirocycloalkyl, double spirocycloalkyl or multiple spirocycloalkyl, preferably single spirocycloalkyl and double spirocycloalkyl. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spirocycloalkyl. "Spiro carbocycle" refers to the ring system in spirocycloalkyl. Non-limiting examples of spirocycloalkyl include:

[0133]

[0134] The term "spiro heterocyclyl" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, and more preferably 7 to 10 yuan. According to the number of shared spiral atoms between rings, the spiral heterocyclic group is divided into a single spiral heterocyclic group, a double spiral heterocyclic group or a multi-spiro heterocyclic group, preferably a single spiral heterocyclic group and a double spiral heterocyclic group. More preferably, it is a 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 5-yuan or 5-yuan / 6-yuan single spiral heterocyclic group. "Spiro heterocycle" refers to the ring system in the spiral heterocyclic group. Non-limiting examples of spiral heterocyclic groups include:

[0135]

[0136] The term "fused ring" refers to a compound in which two or more rings are fused by sharing two adjacent atoms.

[0137] The term "condensed cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of condensed cycloalkyls include:

[0138]

[0139] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. "Fusted heterocycle" refers to the ring system in a fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:

[0140]

[0141] The term "fused heteroaryl" may be an unsaturated fused ring structure with aromaticity containing 5-14 ring atoms (including at least one heteroatom), which is formed by two or more ring structures sharing two adjacent atoms to form a structure, and also includes the case where the carbon atoms, nitrogen atoms and sulfur atoms may be oxidized, preferably "5-12 membered fused heteroaryl", "7-12 membered fused heteroaryl", "9-12 membered fused heteroaryl" and the like, for example, benzofuranyl, benzisofuranyl, benzothiophenyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzotriazolyl, quinolyl, 2-quinolinone, 4-quinolinone, 1-isoquinolinone, isoquinolyl, acridinyl, phenanthridinyl, benzopyridazinyl, phthalazinyl, quinazolinyl, quinoxalinyl, phenolazinyl, pteridinyl, purinyl, naphthyridinyl, phenazinyl, phenothiazinyl and the like. "Fused heteroaryl ring" refers to the ring system in a fused heteroaryl group.

[0142] The term "bridged ring" refers to a structure formed by two or more cyclic structures sharing two non-adjacent ring atoms.

[0143] The term "bridged cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably a bicyclic, tricyclic or tetracyclic, and more preferably a bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:

[0144]

[0145] The term "bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:

[0146]

[0147] The term "alkoxy" refers to an -O-(alkyl) group, wherein alkyl is as defined above.

[0148] The term "hydroxy" refers to -OH.

[0149] The term "thiol" refers to -SH.

[0150] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0151] The term "haloalkyl" refers to an alkyl group substituted with a halogen, wherein alkyl is as defined above.

[0152] The term "cyano" refers to -CN.

[0153] The term "nitro" refers to -NO2.

[0154] The term "amino" refers to -NH2.

[0155] The term "carboxy" refers to -C(O)OH.

[0156] The term "substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort.

[0157] "Substituted by one or more..." means that the compound may be substituted by a single or multiple substituents. When substituted by multiple substituents, the substituents may be the same or a combination of one or more different substituents.

[0158] The term "linked", when referring to a connection between two molecules, means that the two molecules are connected by a covalent bond or the two molecules are associated via a non-covalent bond (eg, a hydrogen bond or an ionic bond), including direct and indirect connections.

[0159] The term "directly connected" refers to a first compound or group connected to a second compound or group without any intervening atoms or groups of atoms. The term "indirectly connected" refers to a first compound or group connected to a second compound or group through an intermediate group, compound or molecule (e.g., a linking group).

[0160] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if there are chiral isomers in the chemical structure, the bond Can be or or include both and Although all of the above structural formulas are drawn as certain isomers for simplicity, the present disclosure may include all isomers, such as tautomers, rotational isomers, geometric isomers, diastereomers, racemates and enantiomers. In the chemical structures of the compounds described in the present disclosure, the bonds No configuration is specified, i.e., the bond The configuration can be E-type or Z-type, or include both E and Z configurations.

[0161] Unless otherwise specified, the symbols used in this article are It means that it can be connected to one or more any groups according to the disclosure described herein.

[0162] In the present disclosure, the terms "comprising" and "including" may be replaced with "consisting of".

[0163] The term "composition" refers to a mixture of a drug and other chemical components containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or precursors, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of the composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.

[0164] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the U.S. Food and Drug Administration for use in humans or domestic animals.

[0165] Unless otherwise specified, the "compounds" of the present disclosure may exist independently in the form of salts, mixed salts or non-salts (such as free acids or free bases). When they exist in the form of salts or mixed salts, they may be pharmaceutically acceptable salts or pharmaceutically usable salts.

[0166] The terms "pharmaceutically acceptable salts" and "pharmaceutically acceptable salts" are used interchangeably and are meant to include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0167] "Pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic acid or an organic acid which retains the biological effectiveness of the free base without other adverse effects and can be prepared by methods known in the art.

[0168] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base which can retain the biological effectiveness of the free acid without other adverse effects. These salts can be prepared by methods known in the art.

[0169] "Effective amount," "effective dose," "therapeutically effective amount," or "therapeutically effective amount" refers to the amount of a drug, compound, or pharmaceutical composition necessary to achieve any one or more beneficial or desired therapeutic results. For prophylactic uses, beneficial or desired results include eliminating or reducing the risk, lessening the severity, or delaying the onset of a condition, including biochemical, histological, and / or behavioral symptoms of the condition, its complications, and intermediate pathological phenotypes present during the development of the condition.

[0170] As used herein, "subject," "patient," "subject," or "individual" are used interchangeably and include humans or non-human animals, such as mammals, such as humans or monkeys. BRIEF DESCRIPTION OF THE DRAWINGS

[0171] Figure 1 The compounds in the examples inhibit the expression of inflammatory factor TNF-α in BV2 cells induced by LPS. Specific implementation plan

[0172] The present disclosure is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present disclosure. Experimental methods in the examples of the present disclosure that do not specify specific conditions are generally performed under conventional conditions or under conditions recommended by raw material or commodity manufacturers. Reagents that do not specify specific sources can be obtained from any supplier of molecular biology reagents with quality / purity for molecular biology applications.

[0173] Unless otherwise specified, the reagents used in the following examples are commercially available products.

[0174] Example 1

[0175] Preparation of (3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidine-1-yl)methanone (1)

[0176] Step 1. Synthesis of methyl 3-bromo-1H-indazole-5-carboxylate

[0177]

[0178] 1.46 g of 1H-indazole-5-carboxylic acid methyl ester (8.30 mmol) was dissolved in 30 mL of DMF, and 1.77 g of NBS (9.96 mmol) was added, and the mixture was heated at 85°C for 12 h. The reaction was detected by TLC, and a large amount of water was added to quench the reaction after the reaction was completed. The mixture was extracted with ethyl acetate three times (30 mL × 3), and the organic layers were combined and washed with saturated brine, dried over anhydrous sodium sulfate for 30 min, and purified by column chromatography (petroleum ether: ethyl acetate = 8:1) to obtain 1.74 g of a white flaky solid with a yield of 82%.

[0179] 1 H NMR (300MHz, DMSO-d6) δ (ppm) 13.81 (s, 1H), 8.19 (dd, J = 1.5, 0.8Hz, 1H), 8.00 (dd, J = 8.8, 1.6Hz, 1H), 7.68 (dd, J = 8.8, 0.8Hz, 1H), 3.88 (s, 3H).

[0180] Step 2. Synthesis of methyl 3-bromo-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate

[0181]

[0182] 1.11 g of methyl 3-bromo-1H-indazole-5-carboxylate (4.35 mmol) was dissolved in 30 mL of DMF, 574 μL of 1,1-difluoro-2-iodoethane (6.52 mmol) and 2.84 g of cesium carbonate (8.70 mmol) were added, and the mixture was heated at 80°C for 12 h. The reaction was detected by TLC. After the reaction was completed, a large amount of water was added to quench the mixture, and the mixture was extracted with ethyl acetate three times (30 mL × 3). The organic layers were combined and washed with saturated brine, dried over anhydrous sodium sulfate for 30 min, and purified by column chromatography (petroleum ether: ethyl acetate = 16:1) to obtain 876 mg of a white flocculent solid with a yield of 63%.

[0183] 1 H NMR (300MHz, DMSO-d6) δ (ppm) 8.20 (dd, J=1.6, 0.7Hz, 1H), 8.08 (dd, J=8.9, 1.6Hz, 1H), 7.9 1(d,J=9.0Hz,1H),6.47(tt,J=54.4,3.4Hz,1H),5.03(td,J=15.5,3.4Hz,2H),3.90(s,3H).

[0184] Step 3. Synthesis of methyl 3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate

[0185]

[0186] 479 mg of 3-bromo-1H-indazole-5-carboxylic acid methyl ester (1.50 mmol) and 365 mg of 5-chlorothiophene-2-boric acid (2.25 mmol) were weighed and placed in a 100 mL two-necked round-bottom flask, and 16 mL of toluene and 8 mL of methanol mixed solvent were added to dissolve, followed by 4 mL of 636 mg of sodium carbonate (6.00 mmol) aqueous solution and 110 mg of [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (0.15 mmol). Under nitrogen protection, the mixture was heated at 110 ° C for 24 h. The reaction was detected by TLC. After the reaction was completed, diatomaceous earth was used for suction filtration, and the organic solvent was removed by vacuum distillation. The mixture was extracted with ethyl acetate three times (30 mL × 3). After the organic layers were combined, they were washed with saturated brine, dried over anhydrous sodium sulfate for 30 min, and purified by column chromatography (petroleum ether: ethyl acetate = 16:1) to obtain 315 mg of a white powdery solid with a yield of 59%.

[0187] 1 H NMR(300MHz,DMSO-d6)δ(ppm)8.64(dd,J=1.5,0.8Hz,1H),8.07(dd,J=8.9,1.5Hz,1H),7.90(d,J=8.9Hz,1H),7.7 1(d,J=4.0Hz,1H),7.28(d,J=3.9Hz,1H),6.49(tt,J=54.5,3.4Hz,1H),5.05(td,J=15.4,3.4Hz,2H),3.91(s,3H).

[0188] Step 4. Synthesis of 3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylic acid

[0189]

[0190] 320 mg of methyl 3-(5-chlorothiophene-2-yl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate (0.93 mmol) was dissolved in 10 mL of methanol, and 209 mg of KOH (3.73 mmol) aqueous solution (2 mL) was added. After heating under reflux at 70°C for 2 hours, TLC monitored the completion of the reaction, and the solvent was distilled off under reduced pressure. After dissolving in water, the pH was adjusted to acidic with 10% dilute hydrochloric acid under ice bath conditions, and a solid was precipitated. After suction filtration and drying, 298 mg of a white powdery solid was obtained with a yield of 97%.

[0191] 1H NMR (300MHz, DMSO-d6) δ (ppm) 13.04 (s, 1H), 8.63 (d, J = 1.4Hz, 1H), 8.06 (dd, J = 8.9, 1.4Hz, 1H), 7.88 (d, J = 8.9H z,1H),7.69(d,J=4.0Hz,1H),7.26(d,J=4.0Hz,1H),6.49(tt,J=54.5,3.4Hz,1H),5.04(td,J=15.4,3.4Hz,2H).

[0192] Step 5. Synthesis of 3-(5-chlorothiophen-2-yl)-N-cyclopropyl-1-(2,2-difluoroethyl)-1H-indazole-5-amide

[0193]

[0194] The product of step 4 (137 mg, 0.40 mmol) and cyclopropylamine (55 μL, 0.80 mmol) were used as raw materials to obtain 96 mg of a white solid with a yield of 60%.

[0195] MP200-202℃, 1 H NMR (300MHz, DMSO-d6) δ8.63 (d, J=3.9Hz, 1H), 8.51 (s, 1H), 7.99

[0196] (dd,J=9.0,1.5Hz,1H),7.83(d,J=8.9Hz,1H),7.79(d,J=4.0Hz,1H),7.31(d,J=3.9Hz,1H),6.47(tt,J=54.6,3 .5Hz,1H),5.01(td,J=15.4,3.5Hz,2H),2.87(tq,J=7.6,3.9Hz,1H),0.78–0.69(m,2H),0.65–0.58(m,2H)ppm; 13 C NMR(101MHz,DMSO)δ167.62,143.30,139.93,134.10,129.05,128.88,128.45,127.29,126.10,1 20.24,119.87,117.11,114.70,112.30,110.88,50.55(t,J=25.3Hz),23.59,6.32ppm.HRMS(ESI + )forC 17 H 14 ClF2N3OS[M+H] + The measured value is 382.0585 and the theoretical value is 382.0584.

[0197] Example 2

[0198] Preparation of azetidin-1-yl(3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)methanone

[0199]

[0200] Referring to the synthesis method of 1, azetidine hydrochloride (45 mg, 0.48 mmol) was used as the raw material to obtain 96 mg of a white solid with a yield of 63%.

[0201] MP108-110℃, 1 H NMR (300MHz, DMSO-d6) δ8.28 (s, 1H), 7.84 (d, J = 8.8Hz, 1H), 7.76

[0202] (dd,J=8.9,1.4Hz,1H),7.72(d,J=4.0Hz,1H),7.25(d,J=4.0Hz,1H),6.48(tt,J=54.6,3.4Hz,1H) ,5.03(td,J=15.4,3.4Hz,2H),4.38(t,J=7.7Hz,2H),4.09(t,J=7.6Hz,2H),2.34–2.20(m,2H)ppm; 13 C NMR (101MHz, CDCl3) δ169.95,142.57,140.85,133.38,130.68,127.43,127.24,126.91,124.69, 121.62, 120.80, 116.14, 113.71, 111.28, 109.38, 53.78, 51.16 (t, J = 28.6Hz), 49.10, 16.12ppm.

[0203] Example 3

[0204] Preparation of (3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3-fluoroazetidyl-1-yl)methanone

[0205]

[0206] Referring to the synthesis method of 1, 3-fluoroazetidine hydrochloride (54 mg, 0.48 mmol) was used as the raw material to obtain 96 mg of a white solid with a yield of 60%.

[0207] MP124-126℃, 1H NMR (300MHz, DMSO-d6) δ8.30 (dd, J=1.4, 0.8Hz, 1H), 7.86 (d, J=

[0208] 8.8Hz,1H),7.78(dd,J=8.9,1.4Hz,1H),7.75(d,J=4.0Hz,1H),7.25(d,J=4.0Hz,1H),6.48(tt,J=54. 6,3.4Hz,1H),5.46(dtt,J=57.6,6.2,3.3Hz,1H),5.03(td,J=15.4,3.5Hz,2H),4.76–4.00(m,4H)ppm; 13 C NMR (101MHz, CDCl3) δ170.38 (d, J = 2.3Hz), 142.75, 140.96, 133.19, 130.86, 127.08, 126.96, 126.77, 124.7 9,121.89,120.88,116.11,113.68,111.24,109.60,83.25,81.22,51.19(t,J=28.6Hz)ppm.HRMS(ESI)forC 17 H 13 ClF3N3OS[M+H] + The theoretical value is 400.0490, and the measured value is 400.0498.

[0209] Example 4

[0210] Preparation of (3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidine-1-yl)methanone

[0211]

[0212] Referring to the synthesis method of 1, 3,3-difluoroazetidine hydrochloride was used as a raw material to obtain 60 mg of a white powdery solid with a yield of 48%.

[0213] MP119-121℃, 1 H NMR(300MHz, DMSO-d6)δ8.34(t,J=1.2Hz,1H),7.88(d,J=9.0Hz,

[0214] 1H),7.82(dd,J=8.9,1.4Hz,1H),7.79(d,J=4.0Hz,1H),7.26(d,J=4.0Hz,1H),6.48(tt,J =54.5,3.4Hz,1H),5.04(td,J=15.5,3.4Hz,2H),4.70(d,J=80.4Hz,4H)ppm.HRMS(ESI)for C 17 H 12 ClF4N3OS[M+H] + :calcd,418.0396; found,418.0401.

[0215] Example 5

[0216] Preparation of (3-(5-chlorothiophen-2-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(morpholinyl)methanone

[0217]

[0218] Referring to the synthesis method of 1, morpholine was used as the raw material to obtain 113 mg of a white solid with a yield of 69%.

[0219] MP141-142℃, 1 H NMR (300MHz, CDCl3) δ8.06 (s, 1H), 7.53 (dd, J = 8.7, 1.4Hz, 1H),

[0220] 7.49(d,J=8.7Hz,1H),7.39(d,J=3.9Hz,1H),6.98(d,J=3.9Hz,1H),6.19(tt,J=55.4,4.3Hz,1H),4.72(td,J=13.4,4.3Hz,2H),3.72(s,8H)ppm; 13 C NMR (101MHz, CDCl3) δ170.15,142.07,140.61,133.33,130.73,129.31,126.91,126.69,124.69, 120.91,120.86,116.15,113.72,111.29,109.71,66.89,51.18(t,J=28.5Hz)ppm.HRMS(ESI)forC 18 H 16 ClF2N3O2S[M+H] + :calcd,412.0686; found,412.0690.

[0221] Example 6

[0222] Preparation of (3,3-difluoroazetidine-1-yl)(1-(2,2-difluoroethyl)-3-(5-methylthiophen-2-yl)-1H-indazol-5-yl)methanone

[0223] Step 1. Preparation of methyl 1-(2,2-difluoroethyl)-3-(5-methylthiophen-2-yl)-1H-indazole-5-carboxylate

[0224]

[0225] Referring to the synthesis method in step 3 of Example 1, (5-methylthiophene-2-yl)boronic acid was used as the raw material to obtain 253 mg of a white solid with a yield of 60%.

[0226] 1 H NMR (300MHz, DMSO-d6) δ8.64(dd,J=1.5,0.8Hz,1H),8.05(dd,J=8.9,1.5Hz,1H),7.87(d,J=8.9Hz,1H),7.58(d,J=3.6Hz, 1H), 6.95 (dd, J=3.6, 1.2Hz, 1H), 6.48 (tt, J=54.6, 3.4Hz, 1H), 5.02 (td, J=15.4, 3.4Hz, 2H), 3.90 (s, 3H), 2.52 (s, 3H)ppm.

[0227] Step 2. Preparation of 1-(2,2-difluoroethyl)-3-(5-methylthiophen-2-yl)-1H-indazole-5-carboxylic acid

[0228]

[0229] Referring to the synthesis method in step 4 of Example 1, 218 mg of a white solid was obtained with a yield of 90%.

[0230] 1 H NMR (300MHz, DMSO-d6) δ13.05(s,1H),8.63(d,J=1.4Hz,1H),8.04(dd,J=8.8,1.5Hz,1H),7.84(d,J=8.9Hz,1H),7.57(d ,J=3.6Hz,1H),6.94(dd,J=3.6,1.3Hz,1H),6.48(tt,J=54.6,3.4Hz,1H),5.02(td,J=15.4,3.5Hz,2H),2.52(s,3H)ppm.

[0231] Step 3. Preparation of (3,3-difluoroazetidin-1-yl)(1-(2,2-difluoroethyl)-3-(5-methylthiophen-2-yl)-1H-indazol-5-yl)methanone

[0232]

[0233] Referring to the synthesis method in step 5 of Example 1, 3,3-difluoroazetidine hydrochloride was used as a raw material to obtain 92 mg of a white solid with a yield of 74%.

[0234] MP106-107℃, 1 H NMR(400MHz, DMSO-d6)δ8.33(t,J=1.1Hz,1H),7.84(d,J=8.9Hz,

[0235] 1H),7.80(dd,J=8.8,1.5Hz,1H),7.66(d,J=3.5Hz,1H),6.93(dd,J=3.6,1.3Hz,1H),6.47(t t,J=54.7,3.5Hz,1H),5.01(td,J=15.3,3.5Hz,2H),4.69(d,J=85.2Hz,4H),2.52(s,3H)ppm. 13 C NMR(101MHz, CDCl3)δ170.96–170.74(m),142.88,142.16,141.12,131.74,126.93,126.17,125.76 ,125.71,122.53,121.14,116.21,115.39,113.78,111.35,109.63,51.14(t,J=28.8Hz),15.42ppm.

[0236] Example 7

[0237] Preparation of (1-(2,2-difluoroethyl)-3-(5-methylthiophen-2-yl)-1H-indazol-5-yl)(morpholinyl)methanone

[0238]

[0239] Referring to the synthesis method of 6, morpholine was used as the raw material to obtain 101 mg of a white solid with a yield of 82%.

[0240] MP161-162℃, 1 H NMR (400MHz, CDCl3) δ8.11 (t, J = 1.1 Hz, 1H), 7.52 (dd, J = 8.7, 1.4

[0241] Hz,1H),7.47(d,J=8.6Hz,1H),7.43(d,J=3.5Hz,1H),6.83(dd,J=3.5,1.3Hz,1 H),6.19(tt,J=55.5,4.4Hz,1H),4.72(td,J=13.3,4.4Hz,2H),3.72(s,8H)ppm; 13 C NMR (101MHz, CDCl3) δ170.40,142.07,141.72,140.83,132.04,128.79,126.59,126.08,125.59 ,121.27,121.10,116.30,113.87,109.55,66.91,51.12(t,J=28.6Hz),15.39ppm.HRMS(ESI)for C 19 H 19 F2N3O2S[M+H] + :calcd,392.1236; found,392.1237.

[0242] Example 8

[0243] Preparation of (3-(2-chloropyridin-4-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidin-1-yl)methanone

[0244] Step 1. Preparation of methyl 3-(2-chloropyridin-4-yl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate

[0245]

[0246] Referring to the synthesis method in step 3 of Example 1, 2-chloro-4-pyridineboronic acid (306 mg, 1.95 mmol, 1.50 eq) was used as a raw material to obtain 252 mg of a white solid with a yield of 55%.

[0247] 1 H NMR (300MHz, DMSO-d6) δ8.65(dd,J=1.5,0.8Hz,1H),8.56(dd,J=5.0,0.8Hz,1H),8.06(dd,J=9.0,1.5Hz,1H),7.97(dd ,J=5.1,1.5Hz,1H),7.94(d,J=9.1Hz,2H),6.52(tt,J=54.4,3.4Hz,1H),5.10(td,J=15.5,3.4Hz,2H),3.88(s,3H)ppm.

[0248] Step 2. Preparation of 3-(2-chloropyridin-4-yl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylic acid

[0249]

[0250] Referring to the synthesis method in step 4 of Example 1, 213 mg of a white solid was obtained with a yield of 90%.

[0251] 1 H NMR (300MHz, DMSO-d6) δ13.15(s,1H),8.70(t,J=1.1Hz,1H),8.61(dd,J=5.1,0.8Hz,1H),8.10(dd,J=8.9,1.4Hz,1H ),8.02(dd,J=6.6,1.4Hz,2H),7.97(d,J=8.9Hz,1H),6.57(tt,J=54.4,3.5Hz,1H),5.15(td,J=15.5,3.4Hz,2H)ppm.

[0252] Step 3. Preparation of (3-(2-chloropyridin-4-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidin-1-yl)methanone

[0253]

[0254] Referring to the synthesis method in step 5 of Example 1, 3,3-difluoroazetidine hydrochloride was used as a raw material to obtain 92 mg of a white solid with a yield of 74%.

[0255] MP154-155℃, 1 H NMR (300MHz, DMSO-d6) δ8.58 (dd, J=5.1, 0.7Hz, 1H), 8.43 (d, J=

[0256] 1.1Hz,1H),8.05(dd,J=5.2,1.5Hz,1H),8.02(dd,J=1.6,0.7Hz,1H),7.95(d,J=8.9Hz,1H),7.85(dd,J= 8.9,1.4Hz,1H),6.55(tt,J=54.4,3.4Hz,1H),5.14(td,J=15.5,3.4Hz,2H),4.69(d,J=82.0Hz,4H)ppm; 13C NMR(101MHz, CDCl3)δ170.66–170.54(m),152.46,150.39,143.17,142.72,142.67,127.08,126 .77,122.05,121.89,121.58,120.24,115.91,115.23,113.48,110.12,51.50(t,J=28.2Hz)ppm.

[0257] Example 9

[0258] Preparation of (3-(2-chloropyridin-4-yl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(morpholinyl)methanone

[0259]

[0260] Referring to the synthesis method of Example 8, morpholine was used as the raw material to obtain 101 mg of a white solid with a yield of 82%.

[0261] MP188-191℃, 1 H NMR (300MHz, CDCl3) δ8.51 (d, J = 5.1Hz, 1H), 8.13 (d, J = 7.1Hz,

[0262] 1H),7.90(d,J=5.7Hz,1H),7.80(d,J=5.6Hz,1H),7.55(d,J=6.7Hz,2H),6 .22(tt,J=55.9,4.7Hz,1H),4.81(td,J=13.3,4.4Hz,2H),3.73(s,8H)ppm; 13 C NMR (101MHz, CDCl3) δ169.95,152.39,150.32,142.91,142.34,142.19,130.21,126.60,121. 83,121.55,120.64,120.21,113.54,110.07,66.85,51.46(t,J=28.2Hz)ppm.HRMS(ESI)forC 19 H 17 ClF2N4O2[M+H] + :calcd,407.1078; found,407.1094.

[0263] Example 10

[0264] Preparation of (3-(3-chloro-4-methoxyphenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidin-1-yl)methanone

[0265] Step 1. Preparation of methyl 3-(3-chloro-4-methoxyphenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate

[0266]

[0267] Referring to the synthesis method in step 3 of Example 1, 3-chloro-4-methoxyphenylboronic acid was used as a raw material to obtain 439 mg of a white powdery solid with a yield of 82%.

[0268] 1 H NMR (300MHz, DMSO-d6) δ8.59(dd,J=1.5,0.7Hz,1H),8.05(dd,J=8.9,1.5Hz,1H),7.95–7.91(m,2H),7.91–7.87(m,1 H),7.37(d,J=8.4Hz,1H),6.53(tt,J=54.7,3.5Hz,1H),5.05(td,J=15.3,3.5Hz,2H),3.95(s,3H),3.90(s,3H)ppm.

[0269] Step 2. Preparation of 3-(3-chloro-4-methoxyphenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylic acid

[0270]

[0271] Referring to the synthesis method in step 4 of Example 1, 432 mg of a white solid was obtained with a yield of 98%.

[0272] 1 H NMR (300MHz, DMSO-d6) δ13.02(s,1H),8.63–8.55(m,1H),8.04(dd,J=8.9,1.4Hz,1H),7.95(d,J=2.0Hz,1H),7.92(dd,J=8.3,2.2 Hz,1H),7.86(d,J=8.9Hz,1H),7.37(d,J=8.5Hz,1H),6.52(tt,J=54.7,3.5Hz,1H),5.04(td,J=15.3,3.5Hz,2H),3.94(s,3H)ppm.

[0273] Step 3. Preparation of (3-(3-chloro-4-methoxyphenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidin-1-yl)methanone

[0274]

[0275] Referring to the synthesis method in step 5 of Example 1, 3,3-difluoroazetidine hydrochloride was used as a raw material to obtain 52 mg of a white solid with a yield of 29%.

[0276] MP126-127℃, 1 H NMR (300MHz, DMSO-d6) δ8.21 (s, 1H), 7.84 (dd, J = 10.7, 2.2Hz,

[0277] 2H),7.76(d,J=8.9Hz,1H),7.71(dd,J=8.9,1.4Hz,1H),7.20(d,J=8.4Hz,1H),6.44(tt ,J=54.7,3.5Hz,1H),4.95(td,J=15.2,3.5Hz,2H),4.86–4.29(m,4H),3.83(s,3H)ppm; 13 C NMR(101MHz, CDCl3)δ171.03–170.91(m),155.62,145.67,143.14,129.41,127.05,126.66,126.00,125 .70,123.38,122.74,121.65,116.29,115.45,113.86,112.43,109.69,56.41,51.22(t,J=28.4Hz)ppm.

[0278] Embodiment 11

[0279] Preparation of (3-(3-chloro-4-methoxyphenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(morpholinyl)methanone

[0280]

[0281] Referring to the synthesis method of Example 10, morpholine was used as the raw material to obtain 108 mg of a white solid with a yield of 62%.

[0282] MP202-203℃, 1 H NMR (300MHz, CDCl3) δ8.07 (s, 1H), 7.94 (d, J = 2.2Hz, 1H), 7.78 (dd,

[0283] J=8.5,2.2Hz,1H),7.50(s,2H),7.05(d,J=8.5Hz,1H),6.20(tt,J=55.5,4. 3Hz,1H),4.75(td,J=13.4,4.1Hz,2H),3.96(s,3H),3.89–3.43(m,8H)ppm;13 C NMR (101MHz, CDCl3) δ170.40,155.37,145.05,142.21,129.26,128.98,126.93,126.33,125.85,123.17,121 .49,121.25,116.27,113.84,112.29,111.41,109.54,66.89,56.30,51.20(t,J=28.4Hz)ppm.HRMS(ESI)for C 21 H 20 ClF2N3O3[M+H] + :calcd,436.1231; found,436.1235.

[0284] Example 12

[0285] Preparation of (3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(morpholinyl)methanone

[0286] Step 1. Preparation of methyl 3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate

[0287]

[0288] Referring to the synthesis method in step 3 of Example 1, 3,4-dichlorophenylboronic acid (365 mg, 2.10 mmol, 1.30 eq) was used as a raw material to obtain 412 mg of a white powdery solid with a yield of 71%.

[0289] 1 H NMR(300MHz,DMSO-d6)δ8.61(dd,J=1.5,0.8Hz,1H),8.13(d,J=2.0Hz,1H),8.07(dd,J=8.9,1.5Hz,1H), 8.00–7.91(m,2H),7.85(d,J=8.4Hz,1H),6.54(tt,J=54.6,3.4Hz,1H),5.09(td,J=15.4,3.5Hz,2H)ppm.

[0290] Step 2. Preparation of 3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylic acid

[0291]

[0292] Referring to the synthesis method in step 4 of Example 1, 417 mg of a white solid was obtained with a yield of 94%.

[0293] 1 H NMR (300MHz, DMSO-d6) δ13.06(s,1H),8.61(d,J=1.3Hz,1H),8.14(d,J=2.0Hz,1H),8.06(dd,J=8.9,1.4Hz,1H),7.97(dd,J= 8.4, 2.1Hz, 1H), 7.91 (d, J = 8.9Hz, 1H), 7.84 (d, J = 8.4Hz, 1H), 6.54 (tt, J = 54.6, 3.4Hz, 1H), 5.08 (td, J = 15.3, 3.5Hz, 2H) ppm.

[0294] Step 3. (3-(3,4-Dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(morpholinyl)methanone

[0295]

[0296] Referring to the synthesis method in step 5 of Example 1, morpholine (70ul, 0.80mmol) was used as the raw material to obtain 120mg of a white solid with a yield of 72%.

[0297] MP154-156℃, 1 H NMR(300MHz,DMSO-d6)δ8.13(d,J=2.1Hz,1H),8.12(s,1H),7.98

[0298] (dd,J=8.4,2.1Hz,1H),7.87(d,J=8.7Hz,1H),7.77(d,J=8.4Hz,1H),7.54(dd,J=8.7,1 .4Hz,1H),6.50(tt,J=54.6,3.4Hz,1H),5.05(td,J=15.3,3.5Hz,2H),3.58(s,8H)ppm; 13 C NMR (101MHz, CDCl3) δ170.21,144.06,142.26,133.27,132.74,132.42,130.97,129.49,129.15, 126.57,126.46,121.45,120.98,113.71,109.73,66.88,51.30(t,J=28.3Hz)ppm.HRMS(ESI)for C 20 H 17 Cl2F2N3O2[M+H] + :calcd,440.0736; found,440.0743.

[0299] Example 13

[0300] Preparation of 1-(4-(3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carbonyl)piperazin-1-yl)ethan-1-one

[0301]

[0302] Referring to the synthesis method of Example 12, N-acetylpiperazine (71ul, 0.60mmol) was used as the raw material to obtain 72mg of a white solid with a yield of 50%.

[0303] MP144-145℃, 1 H NMR (300MHz, CDCl3) δ8.09 (d, J = 1.2 Hz, 1H), 8.03 (d, J = 2.0 Hz,

[0304] 1H),7.77(dd,J=8.3,2.0Hz,1H),7.58(d,J=8.3Hz,1H),7.53(d,J=1.5Hz,2H),6.22(tt ,J=55.3,4.2Hz,1H),4.78(td,J=13.4,4.2Hz,2H),3.84–3.50(m,8H),2.14(s,3H)ppm; 13 C NMR (101MHz, DMSO) δ169.68,168.92,142.55,142.52,133.35,132.31,131.78,131.40,130.30,128.79,127 .61,126.73,120.51,117.23,114.83,112.43,111.30,50.69(t,J=25.3Hz),45.97,21.73ppm.HRMS(ESI)for C 22 H 20 Cl2F2N4O2[M+H] + :calcd,481.1001; found,481.1013.

[0305] Embodiment 14

[0306] Preparation of 1-(3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carbonyl)pyrrolidin-3-one

[0307]

[0308] Referring to the synthesis method of Example 12, 3-pyrrolidone hydrochloride was used as the raw material to obtain 102 mg of a white solid with a yield of 58%.

[0309] MP117-119℃, 1 H NMR (300MHz, CDCl3) δ8.16 (s, 1H), 8.03 (d, J = 2.0Hz, 1H), 7.77 (dd,

[0310] J=8.3,2.1Hz,1H),7.64(dd,J=8.8,1.4Hz,1H),7.58(d,J=8.4Hz,1H),7.54(d,J=8.9Hz,1H),6. 22(tt,J=55.3,4.2Hz,1H),4.78(td,J=13.4,4.2Hz,2H),4.07(s,4H),2.66(t,J=7.8Hz,2H)ppm; 13 C NMR(101MHz,DMSO)δ211.58,169.35,142.70,142.67,133.33,132.31,131.77,131.42,128.81,1 27.62,126.80,120.42,117.23,114.82,112.42,111.24,50.69(t,J=25.2Hz)ppm.HRMS(ESI)for C 20 H 15 Cl2F2N3O2[M+H] + :calcd,438.0579; found,438.0592.

[0311] Embodiment 15

[0312] Preparation of (3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidine-1-yl)methanone

[0313]

[0314] Referring to the synthesis method of Example 12, 3,3-difluoroazetidine hydrochloride (57 mg, 0.44 mmol) was used as a raw material to obtain 76 mg of a white solid with a yield of 43%.

[0315] MP137-138℃, 1 H NMR(300MHz,DMSO-d6)δ8.25(d,J=1.4Hz,1H),8.05(d,J=2.0

[0316] Hz,1H),7.91(dd,J=8.4,2.1Hz,1H),7.83(d,J=8.8Hz,1H),7.76(dd,J=8.9,1.5Hz,1H),7.72(d,J= 8.4Hz, 1H), 6.47 (tt, J = 54.6, 3.4Hz, 1H), 5.01 (td, J = 15.4, 3.4Hz, 2H), 4.63 (d, J = 69.9Hz, 4H) ppm; 13 C NMR(101MHz, CDCl3)δ170.95–170.68(m),144.58,143.08,133.36,132.96,132.17,131.03,129.20, 126.65,126.59,126.38,122.38,121.49,116.07,115.29,113.64,109.79,51.33(t,J=28.4Hz)ppm.

[0317] Example 16

[0318] Preparation of (3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(4-methylpiperazin-1-yl)methanone

[0319]

[0320] Referring to the synthesis method of Example 12, N-methylpiperazine was used as the raw material to obtain 99 mg of a white solid with a yield of 55%.

[0321] MP177-179℃, 1 H NMR (300MHz, CDCl3) δ8.07 (t, J=1.1Hz, 1H), 8.04 (d, J=2.0Hz,

[0322] 1H),7.78(dd,J=8.4,2.0Hz,1H),7.58(d,J=8.3Hz,1H),7.52(d,J=1.3Hz,2H),6.21(tt,J=55 .3,4.2Hz,1H),4.77(td,J=13.4,4.3Hz,2H),3.96–3.51(m,4H),2.44(s,4H),2.33(s,3H)ppm; 13C NMR(101MHz,DMSO)δ169.39,142.47,133.36,132.29,131.76,131.36,130.55,128.76,127.58,1 26.64,120.52,120.30,117.22,114.82,112.41,111.24,54.93,50.69(t,J=25.3Hz),46.08ppm.

[0323] Embodiment 17

[0324] Preparation of (3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(4-hydroxypiperidin-1-yl)methanone

[0325]

[0326] Referring to the synthesis method of Example 12, 4-hydroxypiperidine was used as the raw material to obtain 89 mg of a white solid with a yield of 49%.

[0327] MP106-107℃, 1 H NMR (300MHz, CDCl3) δ8.06 (d, J = 1.2 Hz, 1H), 8.04 (d, J = 2.0 Hz,

[0328] 1H),7.78(dd,J=8.3,2.0Hz,1H),7.58(d,J=8.3Hz,1H),7.52(d,J=1.1Hz,2H),6.22(tt,J=55.3,4.2Hz,1H),4.77(td,J=1 3.4, 4.3Hz, 2H), 4.01 (tt, J = 7.2, 3.4Hz, 1H), 3.36 (s, 2H), 1.89 (d, J = 24.0Hz, 2H), 1.62 (s, 4H), 0.86 (d, J = 6.7Hz, 1H) ppm.

[0329] Embodiment 18

[0330] Preparation of (3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(2-oxa-6-azaspiro[3.3]hept-6-yl)methanone

[0331]

[0332] Referring to the synthesis method of Example 12, 2-oxa-6-aza-spiro[3,3]heptane oxalate was used as the raw material to obtain 73 mg of a white solid with a yield of 40%.

[0333] MP116-118℃,1 H NMR (300MHz, CDCl3) δ8.27 (d, J = 1.3 Hz, 1H), 8.04 (d, J = 2.0 Hz,

[0334] 1H),7.78(dd,J=8.3,2.0Hz,1H),7.73(dd,J=8.8,1.5Hz,1H),7.59(d,J=8.3Hz,1H),7 .51(d,J=8.8Hz,1H),6.22(tt,J=55.3,4.2Hz,1H),4.89–4.70(m,6H),4.44(s,4H)ppm; 13 C NMR (101MHz, DMSO) δ169.42,143.16,142.91,133.24,132.36,131.90,131.51,128.86,127.78,127.62,126.93,12 1.33,120.57,117.22,114.81,112.41,111.18,80.16,62.63,58.44,50.69(t,J=25.4Hz),38.17ppm.HRMS(ESI)for C 21 H 17 Cl2F2N3O2[M+H] + :calcd,452.0736; found,452.0742.

[0335] Embodiment 19

[0336] Preparation of (3-(3,4-dichlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(2-oxa-7-azaspiro[3.5]nonan-7-yl)methanone

[0337]

[0338] 2-Oxa-7-diazaspiro [3.5] nonane-7-carboxylic acid tert-butyl ester (100mg, 0.44mmol) was dissolved in 5ml dichloromethane, and 0.5ml hydrochloric acid dioxane solution was added. After reacting for 2 hours at room temperature, TLC detected that the reaction was complete, and saturated sodium bicarbonate solution was added until no bubbles were generated. After adjusting the pH to 9-10 with sodium hydroxide solution, dichloromethane was extracted three times (5ml×3), and anhydrous sodium sulfate was dried for 30min and then spin-dried to obtain an oily de-Boc product, which was directly used in the next step of reaction. With reference to the synthetic method of Example 12, 100mg of white solid was obtained, and the yield was 52%.

[0339] MP120-121℃, 1H NMR (300MHz, CDCl3) δ8.06 (t, J = 1.1 Hz, 1H), 8.04 (d, J = 2.0 Hz,

[0340] 1H),7.78(dd,J=8.4,2.0Hz,1H),7.58(d,J=8.3Hz,1H),7.52(d,J=1.1Hz,2H),6.22(tt ,J=55.4,4.3Hz,1H),4.77(td,J=13.4,4.2Hz,2H),3.81–3.32(m,8H),1.65(s,4H)ppm; 13 C NMR (101MHz, DMSO) δ169.37,142.45,133.39,132.31,131.78,131.37,130.89,128.79,127.58,126. 54,120.53,120.00,117.23,114.82,112.42,111.25,62.73,50.69(t,J=25.6Hz),50.02,38.64ppm.

[0341] Embodiment 20

[0342] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidyl-1-yl)methanone

[0343] Step 1. Preparation of methyl 3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylate

[0344]

[0345] Referring to the synthesis method in step 3 of Example 1, 3-chlorophenylboronic acid was used as a raw material to obtain 450 mg of a white powdery solid with a yield of 91%.

[0346] 1 H NMR (300MHz, DMSO-d6) δ8.62(dd,J=1.5,0.8Hz,1H),8.07(dd,J=8.9,1.5Hz,1H),7.97–7.94(m,2H),7.94–7.91(m,1H),7.64(t ,J=8.0Hz,1H),7.56(ddd,J=8.1,2.1,1.3Hz,1H),6.54(tt,J=54.5,3.4Hz,1H),5.09(td,J=15.4,3.5Hz,2H),3.90(s,3H)ppm.

[0347] Step 2. Preparation of 3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carboxylic acid

[0348]

[0349] Referring to the synthesis method in step 4 of Example 1, 317 mg of a white solid was obtained with a yield of 94%.

[0350] 1 H NMR (300MHz, DMSO-d6) δ13.08(s,1H),8.65–8.60(m,1H),8.07(dd,J=8.9,1.4Hz,1H),7.97(d,J=1.9Hz,1H),7.95(dd,J=3.0,1.6Hz,1H), 7.92(d,J=8.9Hz,1H),7.64(t,J=8.0Hz,1H),7.57(dt,J=8.2,1.4Hz,1H),6.55(tt,J=54.6,3.5Hz,1H),5.10(td,J=15.4,3.5Hz,2H)ppm.

[0351] Step 3. Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(3,3-difluoroazetidin-1-yl)methanone

[0352]

[0353] Referring to the synthesis method in step 5 of Example 1, 3,3-difluoroazetidine hydrochloride was used as a raw material to obtain 75 mg of a white solid with a yield of 61%.

[0354] MP104-106℃, 1 H NMR (300MHz, DMSO-d6) δ8.34 (dd, J=1.5, 0.8Hz, 1H), 7.97 (d, J=

[0355] 1.6Hz, 2H), 7.90 (d, J=8.8Hz, 1H), 7.82 (dd, J=8.9, 1.5Hz, 1H), 7.61 (dd, J=7.8, 1.6Hz, 1H), 7.55 (dt, J= 8.1,1.4Hz,1H),6.53(tt,J=54.6,3.4Hz,1H),5.09(td,J=15.4,3.5Hz,2H),4.69(d,J=64.6Hz,4H)ppm; 13C NMR (101MHz, CDCl3) δ170.91 (t, J = 3.3Hz), 145.60, 143.07, 135.07, 133.90, 130.35, 129.10, 127.58, 126 .66,126.20,125.66,122.52,121.61,116.14,115.32,113.71,111.28,109.73,51.30(t,J=28.4Hz)ppm.

[0356] Embodiment 21

[0357] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(morpholinyl)methanone

[0358]

[0359] Referring to the synthesis method of Example 20, morpholine was used as the raw material to obtain 63 mg of a white solid with a yield of 52%.

[0360] MP185-186℃, 1 H NMR (400MHz, CDCl3) δ8.11 (t, J = 1.2 Hz, 1H), 7.92 (t, J = 1.8 Hz,

[0361] 1H),7.81(dt,J=7.4,1.6Hz,1H),7.53(d,J=1.2Hz,2H),7.46(t,J=7.7Hz,1H),7.41(dt,J=8 .1,1.7Hz,1H),6.22(tt,J=55.4,4.3Hz,1H),4.78(td,J=13.4,4.3Hz,2H),3.73(s,8H)ppm.

[0362] Embodiment 22

[0363] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(8-oxo-2-azaspiro[4.5]dec-2-yl)methanone

[0364]

[0365] Referring to the synthesis method of Example 20, 53 mg of a white powdery solid product was obtained using 8-oxa-2-azaspiro[4.5]decane with a yield of 65%.

[0366] 1H NMR (300MHz, CDCl3) δ8.18(s,1H),7.92(s,1H),7.82(d,J=6.8Hz,1H),7.64(dd,J=8.7 ,1.4Hz,1H),7.55–7.38(m,3H),6.23(td,J=55.3,4.0Hz,1H),4.78(td,J=14.0,4.4Hz ,2H),3.83–3.74(m,2H),3.67(d,J=19.1Hz,3H),3.60–3.49(m,2H),3.37(s,1H),1.93 (t,J=7.3Hz,1H),1.82(t,J=7.0Hz,1H),1.67(t,J=5.6Hz,2H),1.55(d,J=5.0Hz,2H). 13 C NMR (101MHz, CDCl3) δ145.16,142.30,134.95,134.23,130.27,128.68,127.55,126.48,125.68,121.41,120.95,116.2 3,113.80,111.37,109.46,65.19,64.96,51.27(t,J=28.3Hz),47.86,44.63,40.70,38.62,35.50,34.69ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 24 H 24 ClF2N3O2,460.16034; found460.16213.

[0367] Embodiment 23

[0368] Preparation of 7-(3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carbonyl)-7-azaspiro[3.5]nonan-2-one

[0369]

[0370] Referring to the synthesis method of Example 20, 89 mg of a white powdery solid product was obtained using 7-azaspiro[3.5]nonane-2-one hydrochloride as a raw material with a yield of 67%.

[0371] 1H NMR (300MHz, CDCl3) δ8.09 (s, 1H), 7.92 (d, J = 2.0Hz, 1H), 7.81 (dt, J = 7.2, 1.7Hz, 1H), 7.53 (d, J = 1.1Hz, 2H), 7.49 -7.37(m,2H),6.22(tt,J=55.4,4.2Hz,1H),4.78(td,J=13.4,4.3Hz,2H),3.63(d,J=38.0Hz,4H),2.88(s,4H),1.81(s,4H)ppm. 13 C NMR (101MHz, CDCl3) δ205.91,170.40,145.00,142.21,134.94,134.20,130.29,129.86,128.69,127.51,126.33, 125.64,121.52,120.80,116.23,113.80,111.37,109.65,56.51,51.26(t,J=28.3Hz),29.44,26.91ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 24 H 22 ClF2N3O2,458.1447; found 458.1446.

[0372] Embodiment 24

[0373] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(9-methyl-3,9-diazaspiro[5.5]undecane-3-yl)methanone

[0374]

[0375] Referring to the synthesis method of Example 20, 3-methyl-3,9-diazaspiro[5,5]undecane (61 mg, 0.36 mmol, 1.20 eq) was used as a raw material to obtain 92 mg of a white powdery solid product with a yield of 64%.

[0376] 1H NMR (300MHz, CDCl3) δ8.07(s,1H),7.91(s,1H),7.81(d,J=6.9Hz,1H),7.55(s,2H),7.43(d,J=7.7Hz,2H),6.22(t,J=25.4H z,1H),4.77(dt,J=13.4,7.9Hz,2H),3.59(d,J=29.1Hz,4H),2.70(s,4H),2.53(s,3H),1.79(s,4H),1.72–1.43(m,4H)ppm. 13 C NMR (101MHz, CDCl3) δ170.15,144.96,142.12,134.92,134.26,130.27,130.24,128.62,127.50,126.40,125.64, 121.49,120.69,116.24,113.81,111.38,109.47,51.25(t,J=29.3Hz),51.14,46.39,35.57,29.53ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 26 H 29 ClF2N4O,487.2076; found 487.2060.

[0377] Embodiment 25

[0378] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(6-methoxy-2-azaspiro[3.3]heptane-2-yl)methanone

[0379]

[0380] The raw material 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (250mg, 1.17mmol, 1.00eq) was dissolved in 6mL of anhydrous N,N-dimethylformamide. NaH (56mg, 2.34mmol, 2.00eq) was slowly added under ice bath (0℃), then stirred at room temperature for 30min, and then iodomethane (109μL, 1.76mmol, 1.50eq) was added, and the reaction was continued at room temperature for 1h. After the reaction was detected by TLC, a large amount of water was added to the reaction solution to quench the reaction, and then ethyl acetate was used for extraction three times (20mL×3). The organic phase was collected and combined, and then washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5h, and concentrated under reduced pressure to obtain a colorless oily product methyl ether, which was directly reacted in the next step. The methyl ether was dissolved in 2mL of ethyl acetate, and then 1mL of hydrochloric acid dioxane solution was added, stirred at room temperature for 3h, and spin-dried to obtain a white Boc-free solid product, which was directly reacted in the next step. Referring to the synthesis method of Example 20, 63 mg of yellow-white flaky solid product was obtained with a yield of 48%.

[0381] 1 H NMR (300MHz, CDCl3) δ8.30(s,1H),7.93(s,1H),7.82(dt,J=7.3,1.7Hz,1H),7.75(dd,J=8.8,1.5Hz,1H),7.52–7.40(m,3H),6.22(tt,J=5 5.5,4.3Hz,1H),4.77(td,J=13.4,4.3Hz,2H),4.26(d,J=15.1Hz,4H),3.78(d,J=28.9Hz,1H),3.22(s,3H),2.55(s,2H),2.14(s,2H)ppm. 13 C NMR (101MHz, CDCl3) δ170.08,145.35,142.77,134.95,134.13,130.28,128.72,127.53,126.86,125.66,122 .07,121.47,116.19,113.76,111.33,109.33,69.57,55.47,51.24(t,J=28.3Hz),40.80,38.61ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 23 H 22 ClF2N3O2,446.14469; found446.14389.

[0382] Embodiment 26

[0383] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(2-oxa-6-azaspiro[3.4]octan-6-yl)methanone

[0384]

[0385] Dissolve 2-oxo-6-azaspiro[3,4]octane-6-carboxylic acid tert-butyl ester (60 mg, 0.28 mmol) in 4 mL of dichloromethane, slowly add 0.5 mL of trifluoroacetic acid solution under stirring, and react for 2 h at room temperature. After the reaction is completed by TLC detection, the organic solvent is evaporated under reduced pressure, and the pH is adjusted to 7-8 with saturated sodium bicarbonate solution after adding an appropriate amount of water, and extracted with ethyl acetate three times (15 mL × 3), and the organic phase is collected and combined and washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5 h, and concentrated under reduced pressure to obtain a colorless oily product, which is directly reacted in the next step. Referring to the synthesis method of Example 20, 49 mg of a white powdery solid product is obtained with a yield of 64%.

[0386] 1 H NMR (300MHz, CDCl3) δ8.18(s,1H),7.92(s,1H),7.81(s,1H),7.64(d,J=8.3Hz,1H),7.60–7.36(m,3H), 6.23(t,J=55.4Hz,1H),4.80(s,2H),4.77–4.44(m,4H),3.73(t,J=60.1Hz,4H),2.40–2.09(m,2H)ppm. 13 C NMR (101MHz, CDCl3) δ169.69,145.21,142.37,134.96,134.17,130.28,128.72,127.56,126.46,125.68,121.39 ,121.13,116.22,113.79,111.35,109.48,80.69,80.07,58.22,54.96,51.28(t,J=27.3Hz),48.57ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 22 H 20 ClF2N3O2,432.12904; found 432.12861.

[0387] Embodiment 27

[0388] Preparation of (4-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(6-hydroxy-2-azaspiro[3.4]octan-2-yl)methanone

[0389]

[0390] Referring to the synthesis method of Example 26, 6-hydroxy-2-azaspiro[3.4]octane-2-carboxylic acid tert-butyl ester was used as raw material to obtain 78 mg of a white powdery solid product with a yield of 59%.

[0391] 1 H NMR(400MHz, CDCl3)δ8.33(s,1H),7.93(t,J=1.9Hz,1H),7.82(d,J=7.5Hz,1H), 7.76(dd,J=8.8,1.4Hz,1H),7.52–7.38(m,3H),6.22(tt,J=55.4,4.3Hz,1H),4.7 7(td,J=13.4,4.4Hz,2H),4.43–4.33(m,1H),4.21(d,J=21.9Hz,2H),4.13(s,1H) ,2.16(s,1H),2.08(dd,J=13.9,5.6Hz,1H),1.97(d,J=13.4Hz,2H),1.71(s,4H). 13 C NMR (101MHz, CDCl3) δ170.14,145.40,142.75,134.96,134.12,130.29,128.73,127.55,126.90,125.69,122.18,1 21.49,116.20,113.77,111.34,109.27,73.26,66.98,60.28,51.25(t,J=28.3Hz),40.77,36.61,34.85.HRMS(ESI + ):m / z[M+H] + calculated for C 23 H 22 ClF2N3O2,446.1447; found 446.1425.

[0392] Embodiment 28

[0393] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(piperazin-1-yl)methanone

[0394]

[0395] The raw material (60 mg, 0.179 mmol, 1.00 eq) was dissolved in 6 mL of anhydrous dichloromethane, and EDCI (51 mg, 0.27 mmol, 1.50 eq) and HOBT (36 mg, 0.27 mmol, 1.50 eq) were added in sequence. After stirring at room temperature for 0.5 h for activation reaction, N-Boc-piperazine (40 mg, 0.21 mmol, 1.20 eq) and DIPEA (62 μL, 0.36 mmol, 2.00 eq) were added, and the reaction was continued at room temperature for 3 h. After the reaction was completed by TLC detection, 30 mL of water was added to the reaction solution, and dichloromethane was extracted three times (20 mL × 3). The organic phases were collected and combined, and washed with 1 mol / L hydrochloric acid solution (20 mL × 2), saturated sodium bicarbonate solution (20 mL × 2) and saturated brine (20 mL × 2) in sequence, and dried over anhydrous sodium sulfate for 0.5 h. After the organic phase was concentrated under reduced pressure, column chromatography (dichloromethane: methanol = 100: 1) was performed to obtain a white powder solid intermediate product, which was directly subjected to the next step of reaction. The intermediate was dissolved in 3 mL of dichloromethane, and then 1 mL of trifluoroacetic acid solution was added and stirred at room temperature for 2 h. After the reaction was completed by TLC detection, the organic solvent was evaporated under reduced pressure, and the pH was adjusted to 7-8 with a saturated sodium bicarbonate solution after adding an appropriate amount of water. The product was extracted with ethyl acetate three times (15 mL × 3), and the organic phases were collected and combined, washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5 h, and concentrated under reduced pressure to obtain 47 mg of a white powder solid product with a yield of 65%.

[0396] 1 H NMR (300MHz, CDCl3) δ8.10(s,1H),7.92(t,J=1.9Hz,1H),7.81(dt,J=7.2,1.7Hz,1H),7.52(s,2H),7.49–7.34(m,2H ),6.22(tt,J=55.3,4.2Hz,1H),4.78(td,J=13.4,4.3Hz,2H),3.61(d,J=80.0Hz,4H),2.91(s,4H),1.81(s,1H)ppm. 13 C NMR (101MHz, CDCl3) δ170.27,145.03,142.16,134.97,134.23,130.24,129.90,128.67,127.52,12 6.47,125.63,121.55,120.95,116.23,113.80,111.37,109.53,51.28(t,J=28.3Hz)ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 20 H 19ClF2N4O,405.1294; found 405.1288.

[0397] Embodiment 29

[0398] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(1,3-oxazin-3-yl)methanone

[0399]

[0400] Referring to the synthesis method of Example 20, 1,3-oxazinane was used as the raw material to obtain 67 mg of a white powdery solid product with a yield of 92%.

[0401] 1 H NMR (300MHz, CDCl3) δ8.17(d,J=1.3Hz,1H),7.93(d,J=2.0Hz,1H),7.82(dt,J=7.2,1.7Hz,1H),7.63–7.50(m,2H),7.50– 7.38(m,2H),6.22(tt,J=55.4,4.3Hz,1H),4.95(s,2H),4.78(td,J=13.4,4.3Hz,2H),3.96(t,J=5.3Hz,4H),1.86(s,2H). 13 C NMR (101MHz, CDCl3) δ170.42,145.15,142.43,134.96,134.16,130.24,129.06,128.69,127.52,126. 70,125.66,121.50,116.21,113.78,111.35,109.56,68.26,51.27(t,J=29.3Hz),26.14ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 20 H 18 ClF2N3O2,406.1134; found 406.1136.

[0402] Embodiment 30

[0403] Preparation of (3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)(1,4-oxacyclopentan-4-yl)methanone

[0404]

[0405] Referring to the synthesis method of Example 20, 1,4-oxaazepine was used as the raw material to obtain a colorless oily product, and 67 mg of a white powdery solid was obtained with a yield of 90%.

[0406] 1 H NMR (300MHz, CDCl3) δ8.07(s,1H),7.92(t,J=1.9Hz,1H),7.81(dt,J=7.2,1.7Hz,1H),7.53(s,2H),7.49–7.38(m ,2H),6.22(tt,J=25.4,4.3Hz,1H),4.78(td,J=13.4,4.3Hz,2H),3.97–3.52(m,8H),1.97(d,J=32.2Hz,2H)ppm. 13 C NMR (101MHz, CDCl3) δ171.48,144.98,142.06,134.97,134.23,130.60,130.26,128.67,127.51,126.19,125. 63,121.46,120.25,116.23,113.80,111.37,109.66,71.15,69.59,69.21,51.27(t,J=28.3Hz)ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 21 H 20 ClF2N3O2,420.1290; found420.1279.

[0407] Embodiment 31

[0408] Preparation of 1-(3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazole-5-carbonyl)piperidin-4-one

[0409]

[0410] The raw material 1-(tert-butyloxycarbonyl)-4-piperidone (200mg, 1.00mmol) was dissolved in 4mL of dichloromethane, and 2mL of hydrochloric acid dioxane solution was added, and the mixture was stirred at room temperature for 3h. After the reaction was completed by TLC detection, the solvent was removed by distillation under reduced pressure, and the pH was adjusted to 8-9 with saturated sodium bicarbonate solution after adding an appropriate amount of water. The organic phase was extracted with dichloromethane three times, and then washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5h, and concentrated under reduced pressure to obtain 80mg of a white powder solid intermediate, which was directly used for the next step of reaction. Referring to the synthesis method of Example 20, 62mg of a white powder solid product was obtained, and the yield was 84%.

[0411] 1 H NMR(300MHz, CDCl3)δ8.17(s,1H),7.92(d,J=2.0Hz,1H),7.81(dt,J=7.1,1.7Hz,1H),7.62–7.53(m,2H), 7.49–7.40(m,2H),6.23(tt,J=55.4,4.2Hz,1H),4.79(td,J=13.4,4.3Hz,2H),3.94(s,4H),2.54(s,4H). 13 C NMR (101MHz, DMSO) δ207.82,170.10,143.47,142.58,134.83,134.23,131.51,130.27,128.72,126.86 ,126.49,126.21,120.62,120.36,117.26,114.85,112.45,111.25,50.70(t,J=25.3Hz)ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 21 H 18 ClF2N3O2,418.11339; found 418.11369.

[0412] Embodiment 32

[0413] Preparation of ((1R, 4S)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)(3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)methanone

[0414]

[0415] Referring to the synthesis method of Example 20, 63 mg of a white powdery solid product was obtained using bridged morpholine hydrochloride as a raw material, with a yield of 84%.

[0416] 1H NMR (300MHz, CDCl3) δ8.19(s,1H),7.91(s,1H),7.79(s,1H),7.72–7.57(m,1H),7.53(d,J=8.3Hz,1H),7.46(d,J=8.4Hz,1H),7.42(s,1H),6.2 2(t,J=55.3Hz,1H),5.14–4.39(m,4H),4.20–3.97(m,1H),3.89(d,J=14.6Hz,1H),3.78–3.55(m,1H),3.49(s,1H),1.93(d,J=26.5Hz,2H)ppm. 13 C NMR (101MHz, CDCl3) δ134.98,134.13,130.30,128.73,127.54,126.48,125.67,121.31,116.22,113.78,1 11.35,109.47,75.99,74.25,60.54,58.42,56.86,54.55,51.27(t,J=28.3Hz),37.27,35.73ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 21 H 18 ClF2N3O2,418.1134; found 418.1136.HPLC purity=96.56%,t R =14.05min.

[0417] Embodiment 33

[0418] Preparation of (3,6-diazabicyclo[3.1.1]heptane-3-yl)(3-(3-chlorophenyl)-1-(2,2-difluoroethyl)-1H-indazol-5-yl)methanone

[0419]

[0420] Referring to the synthesis method of Example 20, 6-N-Boc-3,6-diazabicyclo[3.1.1]heptane (43 mg, 0.21 mmol, 1.20 eq) was used as a raw material to obtain a colorless oily intermediate product, which was directly subjected to the next step of reaction. The intermediate was dissolved in 2 mL of ethyl acetate, and then 1 mL of hydrochloric acid dioxane solution was added, and stirred at room temperature for 3 h. After the reaction was completed by TLC detection, the organic solvent was evaporated under reduced pressure, and the pH was adjusted to 7-8 with a saturated sodium bicarbonate solution after adding an appropriate amount of water. The mixture was extracted with ethyl acetate three times (15 mL×3), and the organic phase was collected and combined, washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5 h, and concentrated under reduced pressure to obtain 55 mg of a white powdery solid product with a yield of 73%.

[0421] 1 H NMR (300MHz, CDCl3) δ8.10(s,1H),7.91(s,1H),7.80(d,J=6.7Hz,1H),7.55(s,2H),7.43(d,J=8.8Hz,2H),6.21(t,J=55.0Hz,1H),4.77(td,J=13.3 ,12.9,4.5Hz,2H),4.15(d,J=13.0Hz,1H),3.89(s,2H),3.68(p,J=14.8,1 4.2Hz,3H),2.75(d,J=8.8Hz,1H),2.26(s,1H),0.85(d,J=7.2Hz,1H)ppm. 13 C NMR (101MHz, CDCl3) δ172.61,144.98,142.01,134.94,134.18,130.45,130.28,128.69,127.49,126.04,125 .66,121.46,120.32,113.79,109.80,56.01,55.59,53.32,51.24(t,J=28.3Hz),49.03,30.33ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 21 H 19 ClF2N4O,417.1294; found 417.1285.

[0422] Test example: in vitro enzyme activity evaluation

[0423] The inhibition rate and IC50 of the compound on the enzyme activity of PDE4 were determined by the IMAP-FP method and the coupled enzyme method. The details are as follows:

[0424] Method 1 (IMAP-FP method)

[0425] The specific determination method is as follows:

[0426] (1) Add 40 ml of purified water to 10 ml of 5× IMAP reaction buffer containing 0.1% bovine serum albumin (BSA) provided in the kit to dilute to 1× concentration, and then add DTT to a final concentration of 1 mM to obtain a complete reaction buffer.

[0427] (2) 20 μM fluorescein-labeled cAMP was diluted at a volume ratio of 1:200, that is, 4.5 μL of 20 μM fluorescein-labeled cAMP was added to 900 μL of reaction buffer to make the final concentration 100 nM.

[0428] (3) PDE4B1 and PDE4D3 were diluted to 15 ng / ml with reaction buffer, and the positive drug rolipram and the compound to be tested were diluted to 10 μM and 1 μM with DMSO.

[0429] (4) Add 120 ml of 5× IMAP binding buffer A and IMAP binding buffer B provided in the kit.

[0430] 480 ml of pure water, dilute to 1× concentration. Mix 17 ml of 1× binding buffer A and 3 ml of 1× binding buffer B thoroughly, add 33 μL of binding reagent, mix again to make 20 ml of stop solution, and store at 4°C until use.

[0431] (5) Add 10 μL of enzyme diluent and 10 μL of compound solution to the 96-well plate and incubate at room temperature for 15 minutes before adding

[0432] 10 μL of fluorescein-labeled cAMP dilution was added, sealed and protected from light, and incubated at 25°C for 15 minutes. Finally, 60 μL of stop solution was added to each well, including the blank well, and sealed and protected from light. After incubation at room temperature for 1 hour, the Envision multi-function microplate reader was used to read the data, and the excitation light wavelength was set to 480 nm and the emission light wavelength was set to 535 nm. The collected data was converted into inhibition rate values ​​by calculation.

[0433] Calculation method:

[0434] Inhibition%=(Max-Signal) / (Max-Min)*100%

[0435] Max: fluorescence polarization value of the wells with DMSO and enzyme; Signal: fluorescence polarization value of the wells with inhibitor;

[0436] Min: Fluorescence polarization value of the well with DMSO but no enzyme.

[0437] Method 2 (coupled enzyme method)

[0438] The specific test method is as follows:

[0439] (1) Preparation of compound solution:

[0440] ① Preparation of mother solution (10 mM): Weigh an appropriate amount of compound (0.005 mmol) and dissolve it in 0.5 mL of DMSO. Pipette or shake several times to mix well.

[0441] ②1mM solution: Take 100μL of solution ①, add 900μL of DMSO solution, pipette or shake several times to mix evenly.

[0442] ③100μM solution: Take 100μL of solution ②, add 900μL of DMSO solution, pipette or shake several times to mix well.

[0443] ④10μM solution: Take 100μL of solution ③, add 900μL of DMSO solution, blow or shake several times to mix evenly.

[0444] ⑤1μM solution: Take 100μL of solution ④, add 900μL of DMSO solution, pipette and swirl several times to mix evenly.

[0445] ⑥100nM solution: Take 100μL of solution ⑤, add 900μL of DMSO solution, pipette and swirl several times to mix evenly.

[0446] ⑦10nM solution: Take 100μL of solution ⑥, add 900μL of DMSO solution, pipette and swirl several times to mix well.

[0447] ⑧1nM solution: Take 100μL of solution ⑦, add 900μL of DMSO solution, pipette and vortex several times to mix well.

[0448] ⑨0.1nM solution: Take 100μL of solution ⑧, add 900μL of DMSO solution, pipette and swirl several times to mix evenly.

[0449] ⑩0.01nM solution: Take 100μL of solution ⑨, add 900μL of DMSO solution, pipette and vortex several times to mix well.

[0450] (2) Preparation of mixed solution:

[0451] ① Buffer solution preparation: 20 mL of an aqueous solution containing 61 mM Tris-HCl, 12 mM MgCl2, 61 mM KCl, 6.1 mM TCEP, 0.48 mM PEP, 0.012 mM NADH, and 0.048 mM ATP, pH 8.0.

[0452] ②Myokinase stock solution: Dissolve the enzyme in 2 mL of 3.2 M (NH4)2SO4 distilled water solution, pH = 6.0, containing 0.0001 M EDTA, 10% (m / v) glycerol and 0.01% NaN3 as the stock solution, pipette slowly to mix evenly, divide into 5 tubes, 400 μL / EP tube, re-dissolve in an ice bath for 5 min before use, then re-dissolve at room temperature for 3 min, pipette slowly to mix evenly, and pipette slowly 3 times before sampling.

[0453] ③ Pyruvate kinase stock solution: Dissolve the enzyme in 2 mL of 3.2 M (NH4)2SO4 distilled water solution, pH = 6.0, containing 0.0001 M EDTA, 10% (m / v) glycerol and 0.01% NaN3 as the stock solution, pipette slowly to mix evenly, divide into 10 tubes, 200 μL / EP tube, re-dissolve in an ice bath for 5 min before use, then re-dissolve at room temperature for 3 min, pipette slowly to mix evenly, and pipette slowly 3 times before sampling.

[0454] ④ Lactate dehydrogenase stock solution: Dissolve the enzyme in 50 mL of 3.2 M (NH4)2SO4 distilled water solution, pH = 6.0, containing 0.0001 M EDTA, 10% (m / v) glycerol and 0.01% NaN3 as the stock solution, pipette slowly to mix evenly, divide into 250 tubes, 200 μL / EP tube, re-dissolve in an ice bath for 5 min before use, then re-dissolve at room temperature for 3 min, pipette slowly to mix evenly, and pipette slowly 3 times before sampling.

[0455] ⑤ PDE4B1 stock solution (10nM): Take 10μg of enzyme (MW=109kDa, purity 70%), dissolve in 6.419mL buffer (25mM Tris-HCl, pH8.0, 100mM sodium chloride, 0.05% Tween-20, 50% glycerol and 3mM DTT), slowly blow and mix evenly, divide into 10 tubes, 641.9μL / tube. Redissolve in ice bath for 5min before use, then redissolve at room temperature for 3min, slowly blow and mix evenly, and slowly blow 3 times before sampling.

[0456] ⑥PDE4D3 stock solution (10nM): Take 5μg of enzyme (MW = 102.4kDa, purity 70%), dissolve in 3.416mL buffer (25mM Tris-HCl, pH8.0, 100mM sodium chloride, 0.05% Tween-20, 30% glycerol and 3mM DTT), slowly blow, mix evenly and divide into 5 tubes, 629.2μL / tube. Redissolve in ice bath for 5min before use, then redissolve at room temperature for 3min, slowly blow, mix evenly, and slowly blow 3 times before sampling.

[0457] ⑦ Mixed solution 165μL: take 6μL of myokinase stock solution + 3.2μL of pyruvate kinase stock solution + 2μL of lactate dehydrogenase stock solution + 10μL of PDE4B1 or PDE4D3 stock solution, and make up the rest with 143.8μL of Buffer, pipette slowly and mix evenly.

[0458] (3) Preparation of cAMP solution (0.032 mM):

[0459] Take an appropriate amount of cAMP and prepare 2 mL of 0.032 mM solution with Buffer.

[0460] (4) Operation process:

[0461] ① Prepare a mixed solution in a 96-well plate. First add 143.8μL of Buffer, then add the rest according to the method, pipette slowly and mix evenly.

[0462] ②Add compound solutions in sequence, pipette slowly to mix evenly, and incubate at 25°C for 5 to 10 minutes.

[0463] ③ Before measuring, add cAMP, pipette 3 times, mix well, and measure quickly.

[0464] ④Use microplate reader to measure, with excitation wavelength of 355nM and emission wavelength of 460nM, continue to measure for 10 minutes, and stop the measurement when the platform appears. The initial reaction rate should reach -0.7RFU / s.

[0465] Calculation method:

[0466] Inhibition%=(Max-Signal) / (Max-Min)*100%

[0467] Max: fluorescence intensity of wells without cAMP; Signal: fluorescence intensity of wells with inhibitors;

[0468] Min: fluorescence intensity of wells without inhibitors.

[0469] PDE4 inhibitory activity assay results of compounds 1-21 and 22-33:

[0470] Table 1 Enzyme inhibitory activity of compounds 1 to 21 against PDE4B and PDE4D (IMAP-FP method)

[0471]

[0472]

[0473] Note: The measured inhibition rates are the mean of the results of the two groups

[0474] Table 2 Enzyme inhibitory activity of compounds 22 to 33 against PDE4B and PDE4D (coupled enzyme method)

[0475]

[0476]

[0477] In vitro anti-inflammatory activity evaluation (qRT-PCR method):

[0478] Real-time quantitative PCR (qRT-PCR) was used to detect mRNA expression

[0479] The steps of qRT-PCR are as follows:

[0480] (1) Spray 75% ethanol on the table and wipe it. Use tweezers heated by a lighter to pick up yellow, white, and blue enzyme-free pipette tips and prepare two 1.5 ml enzyme-free EP tubes. Take out the cells and place them on ice. Discard the culture medium. Add PBS to wash twice. Discard the PBS. Then add 600 μL of RNAiso Plus to the culture bottle and gently blow with a 1 ml ordinary pipette tip. Transfer the lysate containing the cells to the enzyme-free EP tube and place it on ice for 15 minutes.

[0481] (2) Add 120 μL of chloroform to the EP tube, vortex to mix, place on ice for 5 minutes, and centrifuge at 12000g for 15 minutes at 4°C. At this time, the liquid in the tube is from top to bottom: colorless supernatant containing RNA, white protein layer containing DNA, and organic liquid layer. Pipette 100 μL of the upper supernatant into another EP tube, add 100 μL of isopropanol, turn the EP tube upside down to mix the liquid thoroughly, and let it stand at room temperature for 10 minutes. Centrifuge at 12000g for 10 minutes at 4°C, discard the supernatant to obtain RNA precipitate. Then add 600 μL of pre-cooled 75% ethanol, shake gently to wash the precipitate, centrifuge at 7500g for 5 minutes at 4°C, and discard the supernatant. Let the EP tube dry at room temperature until the water is completely evaporated and the precipitate becomes translucent, then add 20 μL of DEPC water to dissolve the precipitate.

[0482] (3) After obtaining the total cellular RNA solution, analyze the RNA purity by absorbance. Turn on the UV spectrophotometer, clean the probe twice with anhydrous ethanol and twice with DEPC water; add DEPC water to adjust to zero, and take 2 μL of each sample to detect the RNA concentration. According to the detected RNA concentration, adjust the concentration of each group of samples to about 400 ng / μL with DEPC water.

[0483] (4) Primer design, which was purchased commercially.

[0484] Table 3 Target gene and internal reference primer sequences

[0485]

[0486] According to the instructions of EvoM-MLV RT Kit with gDNA Clean for qPCR, the genome removal reaction mixture was prepared. The standard system was 10 μL. All operation steps were performed on ice to remove residual genomic DNA.

[0487] The system was reacted at 42°C for 2 min.

[0488] The extracted total RNA was then reverse transcribed into cDNA, and all samples were placed in an RNA reverse transcription instrument, incubated at 37°C for 15 min, incubated at 85°C for 5 s, cooled, and temporarily stored at 4°C.

[0489] Quantitative real-time polymerase chain reaction

[0490] (6) Real-time fluorescence quantitative polymerase chain reaction was used to detect the mRNA expression level of TNF-α in bv2 cells in the blank group, model group and treatment group using GAPDH as the standardized internal reference. The cDNAs reverse transcribed at each concentration were diluted to the same concentration and amplified by real-time quantitative PCR on the instrument. Amplification conditions: pre-denaturation at 95°C for 10 minutes, one cycle, then 95°C for 15 minutes, annealing at 60°C for 20 minutes, and extension at 72°C for 20 minutes, 40 cycles. The 2-ΔΔCt method was used for data analysis of qRT-PCR results.

[0491] Three technical replicates were performed for each gene.

[0492] Experimental results:

[0493] The experimental data were processed and analyzed using Graphpad Prism 9.0. All data were expressed as mean ± standard deviation, and significant differences were indicated by P < 0.05.

[0494] The results of compound 5 and 12 inhibiting the expression of inflammatory factor (TNF-α) in BV2 cells induced by LPS are shown in Figure 1 shown.

[0495] The results of qRT-PCR determination of the expression level of TNF-α in the culture supernatant of BV2 cells showed that the expression of TNF-αmRNA induced by LPS could be significantly inhibited. Compound 5 began to show neuroprotective effects at a concentration of 15μM, and the expression level of TNF-αmRNA was reduced compared with the LPS modeling group. Compound 12 can reduce the expression of TNF-αmRNA in a dose-dependent manner, indicating that it can effectively inhibit the inflammatory response of BV2 cells induced by LPS.

Claims

1. A compound as shown in formula I or a pharmaceutically acceptable salt thereof, in, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 1-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 1-3 Substituted 3-6 membered heterocycloalkyl; R 2 is unsubstituted or replaced by R 2-1 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 2-2 substituted 3-6 membered heterocycloalkyl, unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or R 2-5 substituted 5-6 membered heteroaryl; R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl; Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl; R 1-1 and R 3-1 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Carboxyl, -C(=O)-C 1-4 Alkyl, -NHC(=O)-C 1-4 Alkyl or -C(=O)NH-C 1-4 alkyl; R 1-2 , R 1-3 , R 2-1 , R 2-2 , R 2-3 , R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Carboxyl, -C(=O)-C 1-4 Alkyl, -NHC(=O)-C 1-4 Alkyl or -C(=O)NH-C 1-4 alkyl.

2. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, in, R 1 is H, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl; R 2 is unsubstituted or replaced by R 2-3 substituted 3-12 membered heterocycloalkenyl, unsubstituted or replaced by R 2-4 Substituted C 6-14 Aryl, unsubstituted or R 2-5 substituted 5-6 membered heteroaryl; R 3 and R 4 Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl; Or, R 3 and R 4 Together with the nitrogen atom to which it is attached, it forms an unsubstituted or R 3-4 Substituted 3-12 membered heterocycloalkyl; R 1-1 and R 3-1 are each independently a halogen; R 2-3 , R 2-4 , R 2-5 , R 3-2 , R 3-3 and R 3-4 are independently halogen, hydroxyl, thiol, C 1-4 Haloalkyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Carboxyl, -C(=O)-C 1-4 alkyl.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, in, The compound represented by formula I or a pharmaceutically acceptable salt thereof is a compound represented by formula I-1 or a pharmaceutically acceptable salt thereof, Wherein ring A is unsubstituted or substituted by R 3-4 Substituted 3-12 membered heterocycloalkyl, R 1 , R 2 and R 3-4 As defined in claim 1 or 2.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, in, The compound represented by formula I-1 or a pharmaceutically acceptable salt thereof is the compound represented by formula I-1A or a pharmaceutically acceptable salt thereof, 5. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, in, The compound represented by formula I or a pharmaceutically acceptable salt thereof is a compound represented by formula I-2 or a pharmaceutically acceptable salt thereof, Among them, R 3’ and R 4’ Each is independently H, unsubstituted or replaced by R 3-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 3-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 3-3 Substituted 3-12 membered heterocycloalkyl; R 1 , R 2 , R 3-1 , R 3-2 and R 3-3 As defined in claim 1 or 2.

6. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 5, in, The compound represented by formula I-2 or a pharmaceutically acceptable salt thereof is the compound represented by formula I-2A or a pharmaceutically acceptable salt thereof, 7. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, in, The compound represented by formula I or a pharmaceutically acceptable salt thereof is a compound represented by formula I-3 or a pharmaceutically acceptable salt thereof, 8. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, in, The compound represented by Formula I or a pharmaceutically acceptable salt thereof is any of the following structural compounds or a pharmaceutically acceptable salt thereof, 9. A method for preparing a compound as shown in formula I according to any one of claims 1 to 8, wherein include: The compound shown in formula II is subjected to a condensation reaction with the compound shown in formula III to obtain the compound shown in formula I. Among them, R 1 , R 2 , R 3 and R 4 As defined in any one of claims 1 to 8.

10. A pharmaceutical composition comprising a compound of formula I according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

11. Use of a compound of formula I according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 10 in the preparation of a medicament as a PDE4 inhibitor.

12. Use of the compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 10 in the preparation of a medicament for preventing and / or treating a disease associated with PDE4.

13. Use of the compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 10 in the preparation of a medicament for preventing and / or treating inflammatory diseases, fibrotic diseases, injury diseases and central nervous system diseases.

Citation Information

Patent Citations

  • Indazole heterocyclic compound with phosphodiesterase 4B inhibitory activity

    CN111875594A

  • Indazole heterocyclic compound with inhibitory activity on phosphodiesterase 4B

    CN113563319A

  • Thiazolamine MBL inhibitor as well as preparation method and application thereof

    CN116693467A

  • Pyrazole fused ring compound as well as preparation method and application thereof

    CN120265624A

  • Novel 1H-indazole compound

    CN1512987A